Acrivon Therapeutics, Inc. Common Stock (ACRV) — Strategic Asset Allocation Index
Acrivon Therapeutics, Inc. Common Stock (ACRV) has a Strategic Asset Allocation Index of 4.0% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $5.11 Million) total $5.11 Million, measured against net assets of $128.60 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See ACRV net asset quality score to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Acrivon Therapeutics, Inc. Common Stock Strategic Asset Allocation Index (2022–2024)
This chart shows how Acrivon Therapeutics, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the index stands at 4.0%, representing strategic assets of $5.11 Million against net assets of $128.60 Million USD. For live market cap and overall valuation, see Acrivon Therapeutics, Inc. Common Stock (ACRV) market capitalisation.
Annual Strategic Asset Allocation Index for Acrivon Therapeutics, Inc. Common Stock (2022–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Acrivon Therapeutics, Inc. Common Stock from 2022 to 2024, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Acrivon Therapeutics, Inc. Common Stock (ACRV) shareholders funds for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 2.9% | $5.09 Million | $- | $5.09 Million | $176.79 Million | ▲ +2.9 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $121.19 Million | ▼ -25.8 pp |
| 2022 | 25.8% | $43.97 Million | $2.09 Million | $41.88 Million | $170.47 Million | — |